• Je něco špatně v tomto záznamu ?

Current understanding on TREM-2 molecular biology and physiopathological functions

S. Bharadwaj, Y. Groza, JM. Mierzwicka, P. Malý

. 2024 ; 134 (-) : 112042. [pub] 20240503

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013501

Triggering receptor expressed on myeloid cells 2 (TREM-2), a glycosylated receptor belonging to the immunoglobin superfamily and especially expressed in the myeloid cell lineage, is frequently explained as a reminiscent receptor for both adaptive and innate immunity regulation. TREM-2 is also acknowledged to influence NK cell differentiation via the PI3K and PLCγ signaling pathways, as well as the partial activation or direct inhibition of T cells. Additionally, TREM-2 overexpression is substantially linked to cell-specific functions, such as enhanced phagocytosis, reduced toll-like receptor (TLR)-mediated inflammatory cytokine production, increased transcription of anti-inflammatory cytokines, and reshaped T cell function. Whereas TREM-2-deficient cells exhibit diminished phagocytic function and enhanced proinflammatory cytokines production, proceeding to inflammatory injuries and an immunosuppressive environment for disease progression. Despite the growing literature supporting TREM-2+ cells in various diseases, such as neurodegenerative disorders and cancer, substantial facets of TREM-2-mediated signaling remain inadequately understood relevant to pathophysiology conditions. In this direction, herein, we have summarized the current knowledge on TREM-2 biology and cell-specific TREM-2 expression, particularly in the modulation of pivotal TREM-2-dependent functions under physiopathological conditions. Furthermore, molecular regulation and generic biological relevance of TREM-2 are also discussed, which might provide an alternative approach for preventing or reducing TREM-2-associated deformities. At last, we discussed the TREM-2 function in supporting an immunosuppressive cancer environment and as a potential drug target for cancer immunotherapy. Hence, summarized knowledge of TREM-2 might provide a window to overcome challenges in clinically effective therapies for TREM-2-induced diseases in humans.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013501
003      
CZ-PrNML
005      
20240905133828.0
007      
ta
008      
240725e20240503ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.intimp.2024.112042 $2 doi
035    __
$a (PubMed)38703564
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bharadwaj, Shiv $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. Electronic address: shiv.bharadwaj@ibt.cas.cz
245    10
$a Current understanding on TREM-2 molecular biology and physiopathological functions / $c S. Bharadwaj, Y. Groza, JM. Mierzwicka, P. Malý
520    9_
$a Triggering receptor expressed on myeloid cells 2 (TREM-2), a glycosylated receptor belonging to the immunoglobin superfamily and especially expressed in the myeloid cell lineage, is frequently explained as a reminiscent receptor for both adaptive and innate immunity regulation. TREM-2 is also acknowledged to influence NK cell differentiation via the PI3K and PLCγ signaling pathways, as well as the partial activation or direct inhibition of T cells. Additionally, TREM-2 overexpression is substantially linked to cell-specific functions, such as enhanced phagocytosis, reduced toll-like receptor (TLR)-mediated inflammatory cytokine production, increased transcription of anti-inflammatory cytokines, and reshaped T cell function. Whereas TREM-2-deficient cells exhibit diminished phagocytic function and enhanced proinflammatory cytokines production, proceeding to inflammatory injuries and an immunosuppressive environment for disease progression. Despite the growing literature supporting TREM-2+ cells in various diseases, such as neurodegenerative disorders and cancer, substantial facets of TREM-2-mediated signaling remain inadequately understood relevant to pathophysiology conditions. In this direction, herein, we have summarized the current knowledge on TREM-2 biology and cell-specific TREM-2 expression, particularly in the modulation of pivotal TREM-2-dependent functions under physiopathological conditions. Furthermore, molecular regulation and generic biological relevance of TREM-2 are also discussed, which might provide an alternative approach for preventing or reducing TREM-2-associated deformities. At last, we discussed the TREM-2 function in supporting an immunosuppressive cancer environment and as a potential drug target for cancer immunotherapy. Hence, summarized knowledge of TREM-2 might provide a window to overcome challenges in clinically effective therapies for TREM-2-induced diseases in humans.
650    _2
$a lidé $7 D006801
650    12
$a receptory imunologické $x metabolismus $x genetika $7 D011971
650    _2
$a zvířata $7 D000818
650    12
$a membránové glykoproteiny $x metabolismus $x genetika $7 D008562
650    _2
$a signální transdukce $7 D015398
650    _2
$a buňky NK $x imunologie $7 D007694
650    _2
$a přirozená imunita $7 D007113
650    _2
$a T-lymfocyty $x imunologie $7 D013601
650    _2
$a nádory $x imunologie $x metabolismus $x genetika $7 D009369
650    _2
$a fagocytóza $7 D010587
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Groza, Yaroslava $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic
700    1_
$a Mierzwicka, Joanna M $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic
700    1_
$a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. Electronic address: petr.maly@ibt.cas.cz
773    0_
$w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 134 (20240503), s. 112042
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38703564 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133822 $b ABA008
999    __
$a ok $b bmc $g 2143364 $s 1225367
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 134 $c - $d 112042 $e 20240503 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...